An international clinical trial concluded that using a two-stent technique to treat coronary bifurcation lesions with a large stenotic side branch didn't work any better than a provisional stenting approach.
Abbott finally won FDA approval for its MitraClip cardiac device after months of setbacks including an overseas safety warning, mixed study results and a cautious endorsement from a regulatory panel of experts worried about the product's effectiveness.
The Hatch-Waxman Act shook up the generic drugs business in 1984, and almost 30 years later, it's safe to say the law had its desired effect. About 84% of the 4 billion prescriptions written each year are for generic drugs, saving patients and government programs billions of dollars a year. In other words, generic drugs are big business. And with a slew of blockbuster brands now off patent, it's a big business with growing pains.
In its third-quarter earnings report, Abbott surprised investors with a sizable dividend boost, while Actelion assured shareholders it can deliver new profit streams before blockbuster Tracleer goes off patent in 2015. Baxter's report was a little less rosy, with earnings falling on acquisition costs.
Covidien has completed the spinout of its drug business and, as of July 1, is pretty much all about medical devices.
Bioresorbable cardiovascular stents are gaining momentum and drawing more investor interest. This time, the spotlight falls on Amaranth Medical, which is well underway with plans to raise a $25 million Series B funding round.
South Korean scientists believe they may have solved what causes very late stent thrombosis (blood clots) after drug-eluting or bare-metal stent implants. And their solution opens up a door to treating long-term stent patients and helping to boost their survival rates.
When studies of AbbVie's chloesterol drug Niaspan raised questions about its effectiveness, analysts suggested it would lose its blockbuster status. But in the face of falling sales, AbbVie's former parent Abbott Laboratories simply raised the price.
In the fiercely competitive global stent market, Abbott seems to view size as mattering most.
After four years, patients with Abbott's MitraClip cardiac device required additional operations, and the benefits of the device were no better than those of traditional mitral valve surgery, a follow-up look at participants in company's pivotal EVEREST II trial concludes.